Table 3 Multivariable associations between age at MBC diagnosis and OS (N = 3754, Deaths = 1948)

From: The association between young age at metastatic breast cancer diagnosis and overall survival in the EMBRACE study

Variablea

HR (95% CI)

p-value

Age group at MBC diagnosisb

  

≤35 y

1.22 (1.00–1.48)

0.05

>35–45 y

0.94 (0.83–1.07)

0.36

>45–55 y

1.00 (ref)

 

>55–65 y

0.93 (0.82–1.04)

0.20

>65- <75 y

1.15 (1.00–1.33)

0.05

Disease free interval

de novo

1.00 (ref)

 

>0–24 months

2.18 (1.89–2.52)

<0.001

≥24 months

1.22 (1.08–1.38)

0.001

Primary tumor grade

Grade 1

1.00 (ref)

 

Grade 2

1.21 (1.00–1.48)

0.05

Grade 3

1.45 (1.18–1.80)

0.001

Metastatic tumor subtype

Luminal A-like

1.00 (ref)

 

Luminal B-like

1.47 (1.27–1.69)

<0.001

HR + /HER2+

0.59 (0.48–0.73)

<0.001

HR−/HER2+

0.69 (0.55–0.85)

<0.001

HR−/HER2−

2.98 (2.54–3.50)

<0.001

No. of sites of disease

1.07 (1.04–1.10)

<0.001

Sites of disease

Bone

1.21 (1.09–1.33)

<0.001

Brain

1.66 (1.43–1.94)

<0.001

Liver

1.71 (1.55–1.89)

<0.001

Lung

1.10 (0.98–1.23)

0.11

  1. CI confidence interval, HER2 human epidermal growth factor receptor 2, HR + hormone receptor positive, HR− hormone receptor negative, HR hazard ratio, MBC metastatic breast cancer, OS overall survival, y years.
  2. a All variables mutually adjusted.
  3. b (Deaths/N) by age group: ≤35 y (131/240), >35–45 y (372/713), >45–55 y (596/1116), >55–65 y (542/1077), >65–75 y (307/608).
Back to article page